E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Glucose Transporter Type 1 deficiency syndrome |
Syndrome de déficit en transporteur de glucose de type 1 |
|
E.1.1.1 | Medical condition in easily understood language |
Glucose transporter type 1 (Glut1) deficiency syndrome is a rare genetic metabolic disorder characterized by deficiency of a protein that is required for glucose to cross the blood-brain barrier |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10061032 |
E.1.2 | Term | Carbohydrate transport disorder |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary Objectives:
•Evaluate the efficacy and safety of UX007 in the treatment of disabling paroxysmal movement disorders associated with Glut1 DS |
L’objectif principal de l’étude est le suivant :
•Évaluer l’efficacité et la sécurité d’emploi de UX007 dans le traitement des troubles du mouvement paroxystiques handicapants associés au syndrome de déficit en Glut1
|
|
E.2.2 | Secondary objectives of the trial |
Evaluate the efficacy of UX007 compared to placebo, as measured by:
•Walking capacity and endurance, as determined by the distance walked in 12 minutes during the 12 Minute Walk Test (12MWT)
•Health-related quality of life assessing physical function, mobility, upper extremity function, fatigue, pain and social health using a PROMIS®-based questionnaire
•Patient/caregiver global impression of change in clinical status using the Clinical Global Impression – Improvement (CGI-I)
•Duration of disabling paroxysmal movement disorder events observed during the Maintenance Period of treatment, as recorded by the subject/caregiver in an event-based daily electronic Glut1 DS symptom diary
•Cognitive function as measured by the Cambridge Neuropsychological Test Automated Battery (CANTAB) (assessed at select sites)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1)Diagnosis of Glut1 DS confirmed by SLC2A1 mutation
2)Males and females, aged ≥6 years old at the time of informed consent
3)At least 8 disabling paroxysmal movement disorder events in the 12 weeks prior to the Screening, by subject or caregiver report
OR
At least 6 disabling paroxysmal movement disorder events in any 6 consecutive week period, over the last 12 week period prior to the Screening, by subject or caregiver report
4)At least 4 disabling paroxysmal movement disorder events in 6 week Run-in Period, reported in the daily electronic Glut1 DS symptom diary
5)≥80% compliance with daily electronic Glut1 DS symptom diary completion during the Run-in Period
6)Not on KD, modified KD, or ketosis-inducing modified-fat diet for at least 3 months prior to Screening
7)Plasma level of beta-hydroxybutyrate (BHB) ≤ 1 mmol/L (non-fasting) at Screening
8)Provide written or verbal assent (if possible) and written informed consent by the patient (if an adult), or by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures
9)Must, in the opinion of the Investigator, be willing and able to complete key aspects of the study and be likely to complete the 22-week, placebo-controlled, treatment period
10)Patient (or caregiver) must, in the opinion of the Investigator, be able to comply with accurate completion of the study daily electronic Glut1 DS symptom diary
11)Females of child-bearing potential must have a negative urine pregnancy test at Screening and Baseline and be willing to have additional pregnancy tests during the study. Females considered not to be of childbearing potential include those who have not experienced menarche, are post-menopausal (defined as having no menses for at least 12 months without an alternative medical cause) or are permanently sterile due to total hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
12)Participants of childābearing potential or fertile males with partners of child-bearing potential who are sexually active must consent to use a highly effective method of contraception as determined by the site Investigator from the period following the signing of the informed consent through 30 days after last dose of study drug
|
|
E.4 | Principal exclusion criteria |
1)Any known hypersensitivity to triheptanoin or safflower oil that, in the judgment of the Investigator, places the subject at increased risk for adverse effects
2)Prior use of triheptanoin within 30 days prior to Screening
3)History of, or current suicidal ideation, behavior and/or attempts per C-SSRS at Screening or Baseline
4)Pregnant and/or breastfeeding an infant at Screening or Baseline
5)Participants unwilling or unable to discontinue use of a prohibited medication or other substance that may confound study objectives (Section 7.4.6.1 [MCT oil, barbiturates, pancreatic lipase inhibitors, KetoCal or other KD supplements, and/or KD])
6)Glut1 DS treatment regimen, including AEDs, should be stable for at least 30 days prior to Screening
7)Use of any investigational product (drug, medical food, or supplement, including medium chain triglyceride [MCT] oil, including coconut oil) within 30 days prior to Screening
8)Has a concurrent disease or condition, or laboratory abnormality that, in the view of the Investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or introduces additional safety concerns
9)Feeding or nutrition that, in the opinion of the dietitian, potentially affects consistent administration of study drug
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the frequency of disabling paroxysmal movement disorders captured as movement disorder events observed during the Maintenance Period of treatment, as recorded by the subject/caregiver in an event-based daily Glut1 DS symptom diary. |
Critère d’évaluation principal
Le critère d’évaluation principal est la fréquence des troubles du mouvement paroxystiques handicapants mesurés par les événements de trouble du mouvement observés pendant la période d’entretien du traitement, comme consigné dans le journal quotidien des symptômes du syndrome de déficit en Glut1 par le patient/l’aidant.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Daily Glut1 Symptom Diary review: Weeks 0,2,4,6,10,12,14,16,18,22,26,30,34,46,58,70,82,94,106,118,130,142,154,178 |
|
E.5.2 | Secondary end point(s) |
•Walking capacity and endurance, as determined by the distance walked in 12 minutes during the 12 Minute Walk Test (12MWT)
•Health-related quality of life assessing physical function, mobility, upper extremity function, fatigue, pain and social health using a PROMIS®-based questionnaire
•Patient/caregiver global impression of change in clinical status using the Clinical Global Impression – Improvement (CGI-I)
•Duration of disabling paroxysmal movement disorder events observed during the Maintenance Period of treatment, as recorded by the subject/caregiver in an event-based daily electronic Glut1 DS symptom diary
•Cognitive function as measured by the Cambridge Neuropsychological Test Automated Battery (CANTAB) (assessed at select sites)
|
•Capacité de marche et endurance, comme déterminé par la distance de marche en 12 minutes pendant le test de marche de 12 minutes (TM12M)
•Qualité de vie liée à la santé évaluant la fonction physique, la mobilité, la fonction des extrémités supérieures, la fatigue, la douleur et la santé sociale au moyen d’un questionnaire basé sur PROMIS®
•Impression globale de changement de l’état clinique signalée par le patient/l’aidant au moyen de l’échelle d’impression clinique globale - amélioration (Clinical Global Impression - Improvement, CGI-I)
•Durée des événements de trouble du mouvement paroxystiques handicapants observés pendant la période d’entretien du traitement, comme consigné dans le journal quotidien électronique des symptômes du syndrome de déficit en Glut1 par le patient/l’aidant
•Fonction cognitive comme mesuré par le test neuropsychologique de Cambridge à batterie automatique (Cambridge Neuropsychological Test Automated Battery, CANTAB) (évaluée dans certains centres sélectionnés)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
12MWT: Weeks 0,10,12,22
PROMIS: Weeks 0,10,12,22,26,30,34,46,58,70,82,94,106,118,142,154,178
Patient/Caregiver CGI-I: Weeks 10,12,22
Duration of disabling paroxysmal movement disorders:Weeks 0,2,4,6,10,12,14,16,18,22,26,30,34,46,58,70,82,94,106,118,130,142,154,178
CANTAB: Weeks 0,10,12,22 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
open-label Extension Period after the initial 22-week double-blind period |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 11 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
France |
Germany |
Ireland |
Israel |
Italy |
Netherlands |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |